151 related articles for article (PubMed ID: 12517278)
1. Pharmacogenomics and reducing the frequency of adverse drug events.
O'Kane DJ; Weinshilboum RM; Moyer TP
Pharmacogenomics; 2003 Jan; 4(1):1-4. PubMed ID: 12517278
[No Abstract] [Full Text] [Related]
2. Defining the opportunity for pharmacogenetic intervention in primary care.
Grice GR; Seaton TL; Woodland AM; McLeod HL
Pharmacogenomics; 2006 Jan; 7(1):61-5. PubMed ID: 16354125
[TBL] [Abstract][Full Text] [Related]
3. Primum non nocere: adverse drug events must be taken seriously.
Gurwitz D; McLeod HL
Pharmacogenomics; 2007 Apr; 8(4):311-4. PubMed ID: 17391068
[No Abstract] [Full Text] [Related]
4. Pharmacogenomics: historical perspective and current status.
Charlab R; Zhang L
Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
[TBL] [Abstract][Full Text] [Related]
5. From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system.
Wong SH; Happy C; Blinka D; Gock S; Jentzen JM; Donald Hon J; Coleman H; Jortani SA; Lucire Y; Morris-Kukoski CL; Neuman MG; Orsulak PJ; Sander T; Wagner MA; Wynn JR; Wu AH; Yeo KT
Pharmacogenomics; 2010 Jun; 11(6):731-7. PubMed ID: 20504247
[No Abstract] [Full Text] [Related]
6. Pharmacogenomics arrives.
Petsko GA
Genome Biol; 2004; 5(6):108. PubMed ID: 15186481
[TBL] [Abstract][Full Text] [Related]
7. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
Lesko LJ; Zineh I
Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
[TBL] [Abstract][Full Text] [Related]
8. Reducing medical errors and adverse events.
Pham JC; Aswani MS; Rosen M; Lee H; Huddle M; Weeks K; Pronovost PJ
Annu Rev Med; 2012; 63():447-63. PubMed ID: 22053736
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics and public health: implementing 'populationalized' medicine.
Mette L; Mitropoulos K; Vozikis A; Patrinos GP
Pharmacogenomics; 2012 May; 13(7):803-13. PubMed ID: 22594512
[TBL] [Abstract][Full Text] [Related]
10. Special Section on Pharmacogenomics: recent advances and future directions.
Mushiroda T; Giacomini KM; Kubo M
J Hum Genet; 2013 Jun; 58(6):305. PubMed ID: 23797326
[No Abstract] [Full Text] [Related]
11. Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation.
van Schie RM; Cascorbi I; Maitland-van der Zee AH
Pharmacogenomics; 2009 Sep; 10(9):1389-91. PubMed ID: 19761363
[TBL] [Abstract][Full Text] [Related]
12. Biobanking and pharmacogenomics.
McCarty CA; Wilke RA
Pharmacogenomics; 2010 May; 11(5):637-41. PubMed ID: 20415552
[TBL] [Abstract][Full Text] [Related]
13. Is primary care ready for pharmacogenetics?
Voora D; Gage BF
Pharmacogenomics; 2006 Jan; 7(1):1-3. PubMed ID: 16354118
[No Abstract] [Full Text] [Related]
14. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
Alfirevic A; Pirmohamed M
Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of severe cutaneous adverse reactions.
Kaniwa N; Saito Y
Pharmacogenomics; 2013 Apr; 14(6):595-8. PubMed ID: 23570461
[No Abstract] [Full Text] [Related]
16. Canadian adverse events study.
Delaney JA; Palko M; Brennan AS
CMAJ; 2004 Oct; 171(8):833-4; author reply 834. PubMed ID: 15477610
[No Abstract] [Full Text] [Related]
17. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Issa AM
Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
[TBL] [Abstract][Full Text] [Related]
18. Summaries for patients. Emergency department visits for adverse drug events in older adults.
Ann Intern Med; 2007 Dec; 147(11):I24. PubMed ID: 18056655
[No Abstract] [Full Text] [Related]
19. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenomics].
Nakatani K; Nobori T
Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
